Antiphase Boundaries Regulate Phase Stability and Performance in DMA⁺-Assisted CsPbI₃-Based Perovskites.

Authors

Zhi-Wen Yin, Nan Li, Yang Jiang, Xin-Jun Yang, Ji-Hong Zheng, Qi-Bo Yuan, Yu-Chen Wang, Yu-Song Xiao, Jing-Yi Sun, Yan-Bing Chen, Wanchun Xiang, Yu Li, Yi-Bing Cheng, Gustaaf Van Tendeloo, Wei Li, Zhi-Yi Hu

Published in

Advanced materials (Deerfield Beach, Fla.). Pages e74538. Aug 09, 2026. Epub Aug 09, 2026.

Abstract

CsPbI₃-based perovskites are promising absorbers for tandem solar cells owing to their optimal bandgap (∼1.7 eV). However, the phase transition from photoactive γ-CsPbI₃ to non-photoactive δ-CsPbI₃ remains a major obstacle and is strongly governed by microstructural defects formed during film growth. Among these, Ruddlesden-Popper antiphase boundaries (RP-APBs) are particularly prevalent and exhibit competing effects, relieving lattice strain while simultaneously facilitating moisture penetration, ion migration, and nonradiative recombination. Here, we systematically regulate RP-APB defects in γ-phase CsPbI₃ thin films and elucidate their decisive influence on both phase stability and optoelectronic performance. A compositional strategy based on PbI₂ excess effectively reduces RP-APB density but induces edge-sharing [PbI₆]^4- motifs that nucleate the δ phase. In contrast, a dimethylammonium (DMA⁺)-assisted phase-engineering strategy forms β-(DMA,Cs)PbI₃, which intrinsically suppresses RP-APB formation while preserving the photoactive perovskite framework. As a result, RP-APB-free β-phase films exhibit prolonged carrier lifetimes, strongly suppressed nonradiative recombination, and the lowest apparent trap densities, enabling a champion power conversion efficiency of 20.23% together with markedly enhanced operational, thermal, and ambient-air stability. This work demonstrates that regulating crystalline defects, exemplified by RP-APBs, plays a critical role in achieving both stable and efficient perovskite solar cells.

PMID:
42571610
Bibliographic data and abstract were imported from PubMed on 09 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.